Enlaza Therapeutics
La Jolla, California, United StatesFounded 202061+ employeesPrivate
$180M raisedSeries A· last: series unknown (Sep 2025)· 4 rounds
Backed by(11 investors)
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
